Log In
Print
BCIQ
Print
Print this Print this
 

TT-034

  Manage Alerts
Collapse Summary General Information
Company Benitec Biopharma Ltd.
DescriptionDNA-directed RNAi (ddRNAi) adenovirus vector (AAV) containing 3 RNAi elements
Molecular Target
Mechanism of Action 
Therapeutic ModalityGene therapy: Viral vector: Adenovirus
Latest Stage of DevelopmentPhase I/II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 infection; Treat chronic HCV genotype 1 infection in patients who failed prior therapy; Treat hepatitis C virus (HCV)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$1.5M

$1.5M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today